Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Royalty Pharma $1.3 billion senior notes offering
We advised Royalty Pharma on its SEC-registered investment-grade notes offering, including $600 million in social bonds
Natera $584.8 million follow-on offering
We advised the underwriters on the SEC-registered stock offering
TScan Therapeutics $100 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Acutus Medical $77 million follow-on offering
We advised Acutus Medical on the SEC-registered stock offering
Sight Sciences $276 million IPO
We advised the underwriters in connection with the IPO and Nasdaq listing
IVERIC bio $115.2 million stock offering
We advised the underwriters on the SEC-registered equity offering
Kindstar Globalgene Technology HK$2.21 billion IPO
We advised Kindstar Global on its IPO and HKEX listing
IDEAYA Biosciences $92 million follow-on offering
We advised the underwriters on the SEC-registered stock offering
Novo Nordisk acquisition of Neotope Neuroscience
We advised Novo Nordisk on the acquisition
Novo Holdings investment in Availity
We advised Availity on the investment